Recently, Bloomage Biotechnology (Hainan) Corporation Limited, a subsidiary of Bloomage Biotechnology Corporation Limited (688363. SH), formally entered into strategic cooperation with ROHTO Pharmaceutical Co., Ltd. (Hereinafter referred to as ROHTO).and BioMimetics Sympathies (Hereinafter referred to as BMS), and planned to establish joint venture with relevant parties. The joint venture will be located in Haikou National High-tech Zone, Hainan Province, with the main business of conducting research and commercial operation in the field of regenerative medicine and cell culture medium.
.png)
Win-win Co-operation and Enter the Field of Regenerative Medicine
Hainan Free Trade Port is one of the key links in the strategic layout of Bloomage Biotechnology Corporation Limited. At the end of 2020, Bloomage Biotechnology Corporation Limited settled in Hainan Free Trade Port and constructed Bloomage Biotechnology Industrial Park. This project has been listed as a key project of Hainan Province in 2022.
It is reported that the joint venture will enter the industrial park and prioritize the layout of mesenchymal stem cell culture medium. At the same time, Bloomage Biotechnology Corporation Limited will build a production line of regenerative medicine in this industrial park to assist the joint venture to form an industrial ecological chain from R&D to industrialization and commercial operation.
In addition, Bloomage Biotechnology Industrial Park will simultaneously invest and plan the cell culture medium production line meeting the GMP level to support the production of relevant products of the joint venture in the future. It can provide high-performance and cost-effective cell culture medium series for China's biomedical industry, and assist the development of Chinese medical industry.
This cooperation will make full use of various advantages, break technical barriers with advanced regenerative medicine technology and promote the high-quality development of China's regenerative medicine field. Through this cooperation, Bloomage Biotechnology Corporation Limited formally entered the field of regenerative medicine, which is expected to further develop its core advantages in research and development and scientific and technological innovation at the bottom level, bringing strong kinetic energy to the development of Hainan Free Trade Port.
Carry out Layout to research "Biochip"
Cell culture medium has been praised as the "chip force" of the global biomedical industry, and the preparation and production of biological products are highly dependent on the cell culture medium. At the same time, cell culture medium is also a key consumable for scientific research in biology and medicine.
In recent years, the rapid development of the global biomedical industry and the impact of COVID-19, the research and development of antibody drugs, vaccines and cell therapy products have been increasing rapidly. This drives the rapid development of the upstream industry of biological products and increases the market demand of culture media. It is predicted that the total market of global cell culture medium will reach USD 8.24 billion in 2028(data source: China Economic Research Institute). In addition, localization substitution trend and overseas medical market expansion will also become the key growth point of culture medium industry in the future.
As a scientific and technological innovation-oriented enterprise, Bloomage Biotechnology Corporation Limited, driven by synthetic biotechnology, has always taken science and technology as the base of enterprise development. It insists on continuous investment in basic research and applied basic research, and masters many key core technologies in many industries such as microbial fermentation, enzyme digestion technology and cross linking technology. It also possesses more than 20 years of medical gene and rich medical experience, with a leading industrialization capability.
This layout of regenerative medicine and cell culture medium industry is another important strategic layout of Bloomage Biotechnology Corporation Limited in bottom scientific research. It will further enrich the core technology matrix of Bloomage Biotechnology Corporation Limited, strengthen scientific research barrier and competitive advantage, and consolidate the leading position of the industry. At the same time, this will further enhance the core technical strength of China's regenerative medicine and cell culture medium industry, and help the national strategy of "scientific and technological make a powerful nation " in the field of biotechnology.
ROHTO Pharmaceutical Co., Ltd. (Hereinafter referred to as "ROHTO ") puts forward the comprehensive business outlook of 2030 “Connect for Well-being”. Besides the production and sales of OTC’s highest market share of eye medicines and pharmaceutical products, cosmetics, functional foods, etc., it is committed to regenerative medicine as one of the expansion fields of the business. Study on the use of adipose-derived mesenchymal stem cells to solve the disease needs without definite treatment methods, and to produce, manufacture and market the medium (AOF medium) without animal and human origin which is born in the research and development process.
.jpg)
BioMimetics Sympathies (Hereinafter referred to as"BMS") is a regenerative medicine R&D enterprise for customized cell culture media for the purpose of cell-targeted therapy for specific diseases. Its culture medium is characterized by the absence of raw materials of human or animal origin, while contributing to the development of regenerative medicine by providing specialized cell culture techniques while being safe and effective. At present, BMS takes advantage of its professional experience accumulated in the development of mesenchymal stem cell culture medium for many years. It not only carries out the entrusted development of external enterprises, but also actively authorizes its own high-value-added media technology.
